News

Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.
Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS
Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...
Sarepta sinks 9% after Elevidys studies placed on hold in Europe
The shares are down 9%, or $5.53, to $56.94 in premarket trading. Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended ...
Sarepta’s Gene Therapy Under Scrutiny After Patient Death
Shares of Sarepta, based in Cambridge, Massachusetts, dropped more than 27% on Tuesday, closing at about $73 per share. Elevidys, which costs $3.2 million for a one-time infusion, was the first gene ...